Nonpeptidic potent HIV-1 protease inhibitors.
Jagdish Prasad(Pfizer (United States)), John W. Erickson(National Institutes of Health), Peter J. Tummino(Intarcia Therapeutics (United States)), David M. Ferguson(University of Minnesota), Donald Hupe(Pfizer (United States)), K. S. Para, J. M. DOMAGALA(Gaertner (United States)), Elizabeth A. Lunney(Pfizer (United States))
PubMed
April 1, 1996
Cited by 12
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
|Biochemistry|2008|550